<DOC>
	<DOCNO>NCT00980018</DOCNO>
	<brief_summary>The purpose exploratory study examine change chronic low grade chronic adverse event , measure Common Terminology Criteria Adverse Events ( CTCAE ) grading , patient switch imatinib nilotinib therapy .</brief_summary>
	<brief_title>An Exploratory Trial Assess Improvement Adverse Events Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched Nilotinib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female patient â‰¥ 18 year age 2 . ECOG 0 , 1 , 2 3 . Diagnosis CMLCP associate BcrAbl quantifiable RQPCR ( IS ) 4 . Patients must imatinib responder achieve follow efficacy milestone appropriate length time imatinib therapy per protocol 5 . CMLCP patient initiate dose imatinib 6 . Ability provide write informed consent prior study related screening procedure do 1 . Loss CHR cytogenetic response 2 . Prior accelerate phase blast phase CML 3 . Previously document T315I mutation 4 . Presence chromosomal abnormality ( trisomy 8 ) and/or clonal evolution Ph+ . 5 . Previous treatment tyrosine kinase inhibitor except imatinib . 6 . Treatment investigational agent within 30 day Day 1 . 7 . History noncompliance medical regimen inability grant consent . 8 . Women pregnant , breast feeding , childbearing potential without negative serum test baseline . Male female patient childbearing potential unwilling use contraceptive precaution throughout trial 3 month follow discontinuation study drug . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Women childbearing potential must negative serum pregnancy test prior first dose nilotinib . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>CML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Tasigna</keyword>
	<keyword>nilotinib</keyword>
	<keyword>AMN107</keyword>
	<keyword>CML-CP</keyword>
	<keyword>Chronic Phase</keyword>
</DOC>